By 2040, there will be
over 700 million people
with diabetes
100% of patients with Type 1 diabetes
>60% of patients with Type 2 diabetes
will develop diabetic retinopathy (DR)
Two patent families with strong claims covering key markets: US, Canada, EU, China, etc.
Patent family 1: WO2022006667
Priority: July 2020
In national phase
Patent family 2: WO2025175400
Priority: Feb 2024
PCT Published
DR2 preclinical development through phase I
Partnering for phase II/phase III
Ongoing engagement with industry, clinical stakeholders to prepare for IND and phase 1
Devising strategy with reference to existing siRNA therapeutics on the market for other condition
Engaging regulatory bodies early and regularly
Partnering with regulatory consultants in key markets
Pursuing diversified funding (grants, F&F, non-dilutable)
Innovation & grant ecosystem engagement
Milestone-based fundraising
YEAR
Report of Invention
First US Provisional Filing
i-RNA Incorporated
IP Licensed from Western U​
First PCT Filing
Early Validation
Second PCT Filing
Pre-clinical Validation (eyedrop delivery)
IND-Enabling studies
Regulatory Preparation
Phase 1 Clinical Trial
​
Phase 2 trial
Strategic partnerships
